Abstract Details

Title Combined Measures of Brain Structural Damage and Clinical Relapses Correlate with Long-Term Disability Changes in Relapsing Multiple Sclerosis

Topic MS and Related Diseases

Presentation(s) P04 - (-)

Poster/Presentation
Number 126

Objective

Background BACKGROUND: A number of studies have variably associated MRI measures with disease progression in MS. However, such relationship is largely unknown in the long term.

Design/Methods DESIGN/METHODS: In this ongoing study, we acquired thus far conventional brain MRI in 82 MS patients (56 females; age=37.3±9.9 years; 70 relapsing-remitting [RR], 7 secondary progressive [SP] and 5 primary progressive) at baseline and after 10 years, using the same MRI protocol. Brain lesion volume (LV), baseline normalized brain volume (NBV) and the 10-year percent brain volume change (PBVC) were computed.

Results RESULTS: After 10 years, disease course remained RR in 61 patients and turned into SP in 5 RR patients. In the relapsing group, EDSS increased from 1.8±1.1 to 2.6±1.7 and relapse number was 3.9±3.6. Brain LV increase during follow-up was 2.5±5 cm3 for T2 lesions, 2±3 cm3 for T1 lesions, while PBVC decreased of -5.3±2.2%. At the univariate analysis, 10-year EDSS change correlated significantly with baseline NBV (r=-0.31), T2 (r=0.46) and T1 (r=0.35) LVs. Significant correlation was also found between 10-year change in EDSS and MRI measures (T2-LV: r=0.37; T1-LV: r=0.46; PBVC: r=-0.30). Over 10 years, EDSS worsening was also significantly associated with relapse number (r=0.55). At the multivariate analysis, baseline NBV, 10-year PBVC and T1-LV increase were significant MRI predictors of 10-year disability worsening (r=0.65). Such correlation was even closer when the relapse number was added to the MRI model (r=0.70).

Conclusions CONCLUSIONS: These findings add long-term evidence in suggesting that the combined use of MRI measures of focal and diffuse tissue damage alone or with clinical relapses can explain most of the long-term disability progression in patients with MS.

Authors/Disclosures
Antonio Giorgio, MD PRESENTER	Dr. Giorgio has nothing to disclose.
Maria Laura Stromillo, PhD (Policlinico Le Scotte)	Maria Laura Stromillo, PhD has nothing to disclose.
	No disclosure on file
Francesca Rossi, PhD (Universita Degli Studi di Siena)	No disclosure on file
	No disclosure on file
	No disclosure on file
Robert G. Holloway, MD, MPH, FAAN (University of Rochester Medical Center)	Dr. Holloway has nothing to disclose.
	No disclosure on file
Leonello Guidi, MD	No disclosure on file
Emilio Portaccio	Emilio Portaccio has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Emilio Portaccio has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono. Emilio Portaccio has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Emilio Portaccio has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Emilio Portaccio has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Emilio Portaccio has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen. Emilio Portaccio has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck Serono. Emilio Portaccio has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Emilio Portaccio has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Emilio Portaccio has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Emilio Portaccio has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS Cellgene.
Maria P. Amato, PhD (Ospedale Di Careggi)	Dr. Amato has received personal compensation for serving as an employee of AOUCareggi. Dr. Amato has received personal compensation for serving as an employee of AOUCareggi. Dr. Amato has received personal compensation for serving as an employee of AOUCareggi. Dr. Amato has received personal compensation for serving as an employee of AOU Careggi. Dr. Amato has received personal compensation for serving as an employee of AOUCareggi. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi Genzyme. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi genzyme. The institution of Dr. Amato has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene BMS. The institution of Dr. Amato has received research support from Merck. The institution of Dr. Amato has received research support from Biogen. The institution of Dr. Amato has received research support from Roche.
	No disclosure on file
Nicola De Stefano, MD (University of Siena)	Dr. De Stefano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck Healthcare KGaA. Dr. De Stefano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunic AG. Dr. De Stefano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis Pharma AG. Dr. De Stefano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck Serono S.p.A. Dr. De Stefano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. De Stefano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche S.p.A.. The institution of Dr. De Stefano has received research support from Italian MS Society. The institution of Dr. De Stefano has received research support from Merck Healthcare KGaA.

��ɫ��

��ɫ��